Fractional doses of inactivated poliovirus vaccine in Oman
- PMID: 20573923
- DOI: 10.1056/NEJMoa0909383
Fractional doses of inactivated poliovirus vaccine in Oman
Abstract
Background: We conducted a clinical trial of fractional doses of inactivated poliovirus vaccine administered to infants in Oman, in order to evaluate strategies for making the vaccine affordable for use in developing countries.
Methods: We compared fractional doses of inactivated poliovirus vaccine (0.1 ml, representing one fifth of a full dose) given intradermally with the use of a needle-free jet injector device, with full doses of vaccine given intramuscularly, with respect to immunogenicity and reactogenicity. Infants were randomly assigned at birth to receive either a fractional dose or a full dose of inactivated poliovirus vaccine at 2, 4, and 6 months. We also administered a challenge dose of monovalent type 1 oral poliovirus vaccine at 7 months and collected stool samples before and 7 days after administration of the challenge dose.
Results: A total of 400 infants were randomized, of whom 373 (93.2%) fulfilled the study requirements. No significant baseline differences between the groups were detected. Thirty days after completion of the three-dose schedule, the rates of seroconversion to types 1, 2, and 3 poliovirus were 97.3%, 95.7%, and 97.9%, respectively, in the fractional-dose group, as compared with 100% seroconversion to all serotypes in the full-dose group (P=0.01 for the comparison with respect to type 2 poliovirus; results with respect to types 1 and 3 poliovirus were not significant). The median titers were significantly lower in the fractional-dose group than in the full-dose group (P<0.001 for all three poliovirus serotypes). At 7 months, 74.8% of the infants in the fractional-dose group and 63.1% of those in full-dose group excreted type 1 poliovirus (P=0.03). Between birth and 7 months, 42 hospitalizations were reported, all related to infectious causes, anemia, or falls, with no significant difference between vaccination groups.
Conclusions: These data show that fractional doses of inactivated poliovirus vaccine administered intradermally at 2, 4, and 6 months, as compared with full doses of inactivated poliovirus vaccine given intramuscularly on the same schedule, induce similar levels of seroconversion but significantly lower titers. (Current Controlled Trials number, ISRCTN17418767.)
2010 Massachusetts Medical Society
Comment in
-
The bumpy road to polio eradication.N Engl J Med. 2010 Jun 24;362(25):2346-9. doi: 10.1056/NEJMp1005405. N Engl J Med. 2010. PMID: 20573922 No abstract available.
-
Poliovirus vaccine and vaccine-derived polioviruses.N Engl J Med. 2010 Nov 4;363(19):1870; author reply 1870-1. doi: 10.1056/NEJMc1009551. N Engl J Med. 2010. PMID: 21047242 No abstract available.
Similar articles
-
Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba.J Infect Dis. 2010 May 1;201(9):1344-52. doi: 10.1086/651611. J Infect Dis. 2010. PMID: 20350164 Clinical Trial.
-
Priming after a fractional dose of inactivated poliovirus vaccine.N Engl J Med. 2013 Jan 31;368(5):416-24. doi: 10.1056/NEJMoa1202541. N Engl J Med. 2013. PMID: 23363495 Clinical Trial.
-
Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults.Vaccine. 2013 Aug 12;31(36):3688-94. doi: 10.1016/j.vaccine.2013.05.104. Epub 2013 Jun 13. Vaccine. 2013. PMID: 23770332 Clinical Trial.
-
Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule.Vaccine. 2017 May 19;35(22):2993-2998. doi: 10.1016/j.vaccine.2017.03.008. Epub 2017 Apr 20. Vaccine. 2017. PMID: 28434691 Free PMC article. Review.
-
Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis.J Infect Dis. 2014 Nov 1;210 Suppl 1(Suppl 1):S439-46. doi: 10.1093/infdis/jit601. Epub 2014 Mar 14. J Infect Dis. 2014. PMID: 24634499 Free PMC article. Review.
Cited by
-
Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance.Pathogens. 2024 Mar 4;13(3):224. doi: 10.3390/pathogens13030224. Pathogens. 2024. PMID: 38535567 Free PMC article. Review.
-
High levels of maternally derived antibodies do not significantly interfere with the development of humoral and cell-mediated responses to Porcine circovirus 2 after intradermal vaccination.Porcine Health Manag. 2023 Sep 15;9(1):40. doi: 10.1186/s40813-023-00335-9. Porcine Health Manag. 2023. PMID: 37715214 Free PMC article.
-
Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.Hum Vaccin Immunother. 2022 Dec 30;18(7):2154100. doi: 10.1080/21645515.2022.2154100. Epub 2022 Dec 28. Hum Vaccin Immunother. 2022. PMID: 36576132 Free PMC article. Review.
-
Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey.Lancet Reg Health Am. 2022 Jul;11:None. doi: 10.1016/j.lana.2022.100235. Lancet Reg Health Am. 2022. PMID: 35865654 Free PMC article.
-
One Full or Two Fractional Doses of Inactivated Poliovirus Vaccine for Catch-up Vaccination in Older Infants: A Randomized Clinical Trial in Bangladesh.J Infect Dis. 2022 Oct 17;226(8):1319-1326. doi: 10.1093/infdis/jiac205. J Infect Dis. 2022. PMID: 35575051 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical